产品
编 号：F099384
分子式：C36H51Cl2N3O4
分子量：660.71
分子式：C36H51Cl2N3O4
分子量：660.71
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1259305-29-7
产品详情
生物活性：
Aripiprazole lauroxil, an N-acyloxymethyl proagent of aripiprazole, is a Long-acting injectable (LAI) typical antipsychotic for schizophrenia. Aripiprazole lauroxil is cleaved by body’s enzyme esterase to N-hydroxymethyl aripiprazole (plus lauric acid) and then to aripiprazole (plus formaldehyde), no toxicity.
体内研究：
Aripiprazole lauroxil (静脉给药；1.87 mg/mL) 的体内生物转化涉及中间体 N-羟甲基阿立哌唑的形成，体外数据表明 Aripiprazole lauroxil 具有高生物转化率，因此，观察到的 N-羟甲基阿立哌唑浓度在服用月桂酰阿立哌唑的动物体内含量惊人地高。Animal Model:Female Sprague Dawley rats
Dosage:1.87?mg/ml?
Administration:Blood samples is taken at 5, 15, 30?min and 1, 2, 4, 6, 8 and 24?h after administration
Result:Exhibits an clearance: 0.32?±?0.11?L/h/kg.?
Aripiprazole lauroxil, an N-acyloxymethyl proagent of aripiprazole, is a Long-acting injectable (LAI) typical antipsychotic for schizophrenia. Aripiprazole lauroxil is cleaved by body’s enzyme esterase to N-hydroxymethyl aripiprazole (plus lauric acid) and then to aripiprazole (plus formaldehyde), no toxicity.
体内研究：
Aripiprazole lauroxil (静脉给药；1.87 mg/mL) 的体内生物转化涉及中间体 N-羟甲基阿立哌唑的形成，体外数据表明 Aripiprazole lauroxil 具有高生物转化率，因此，观察到的 N-羟甲基阿立哌唑浓度在服用月桂酰阿立哌唑的动物体内含量惊人地高。Animal Model:Female Sprague Dawley rats
Dosage:1.87?mg/ml?
Administration:Blood samples is taken at 5, 15, 30?min and 1, 2, 4, 6, 8 and 24?h after administration
Result:Exhibits an clearance: 0.32?±?0.11?L/h/kg.?
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备